Organogenesis Holdings (ORGO) Non-Current Deffered Revenue (2016 - 2020)
Organogenesis Holdings (ORGO) posted quarterly Non-Current Deffered Revenue of $1.1 million for Q3 2020, up 49.18% year-over-year from $736000.0 in Q4 2019, and little changed quarter-over-quarter from $1.1 million in Q2 2020.
Organogenesis Holdings (ORGO) Non-Current Deffered Revenue (2016 - 2020) Analysis & Trends
Organogenesis Holdings' Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $1.1 million for Q3 2020.
- In Q3 2020, Non-Current Deffered Revenue rose 49.18% year-over-year to $1.1 million; the TTM figure through Sep 2020 stood at $1.1 million (up 49.18% YoY), while the FY2019 annual figure was $1.0 million, up 678.46% from the prior year.
- Non-Current Deffered Revenue for Q3 2020 stood at $1.1 million, roughly flat from $1.1 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $10.8 million in Q4 2016, with the low at $52000.0 in Q1 2019.
- The 5-year median for Non-Current Deffered Revenue is $1.1 million (2020), against an average of $4.7 million.
- The sharpest annual moves came in 2019 and 2020: Non-Current Deffered Revenue slumped 99.52% in 2019, then surged 2025.0% in 2020.
- Organogenesis Holdings' Non-Current Deffered Revenue stood at $10.8 million in 2016, then tumbled by 99.32% to $74000.0 in 2017, then jumped by 75.68% to $130000.0 in 2018, then soared by 678.46% to $1.0 million in 2019, then grew by 8.5% to $1.1 million in 2020.
- Business Quant data shows ORGO's Non-Current Deffered Revenue at $1.1 million in Q3 2020, $1.1 million in Q2 2020, and $1.1 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Organogenesis Holdings | 229.04 Mn | 182.20 Mn | 20.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 1.10 Mn |
| Jun 30, 2020 | 1.10 Mn |
| Mar 31, 2020 | 1.11 Mn |
| Dec 31, 2019 | 1.01 Mn |
| Sep 30, 2019 | 736,000.00 |
| Jun 30, 2019 | 456,000.00 |
| Mar 31, 2019 | 52,000.00 |
| Dec 31, 2018 | 130,000.00 |
| Sep 30, 2018 | 5.13 Mn |
| Jun 30, 2018 | 10.85 Mn |
| Mar 31, 2018 | 10.85 Mn |
| Dec 31, 2017 | 74,000.00 |
| Sep 30, 2017 | 10.85 Mn |
| Jun 30, 2017 | 10.85 Mn |
| Mar 31, 2017 | 10.85 Mn |
| Dec 31, 2016 | 10.85 Mn |